Corgenix Medical Corp. has entered into a collaboration agreement with Eli Lilly and Company to develop diagnostic technology in support of a Lilly oncology pipeline program. Under the terms of the agreement, the two companies will collaborate to further advance this proprietary diagnostic technology originally developed by Lilly. The financial terms of the agreement were not disclosed. The collaboration with Lilly is part of Corgenix' recently announced expansion of its Contract Services Business Unit for contract product development, technology application and manufacturing for the healthcare and biotechnology industries.

Eli Lilly and Company announced Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL). The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were consistent with previously disclosed studies.

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced results from two new pooled analyses of phase III data with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, presented at the American Association of Clinical Endocrinologists (AACE) 22(nd) Annual Scientific & Clinical Congress. In one retrospective pooled analysis, data were included from Hispanic/Latino adults with type 2 diabetes (T2D), a population that is disproportionately affected by T2D. Data pooled from six phase III studies showed that treatment with linagliptin reduced glucose levels (HbA(1c)) versus placebo in this patient population. In a second retrospective analysis, data were pooled from two phase III studies that included people with long-standing T2D (>/=10 years). The analysis showed reductions in HbA(1c) from baseline with linagliptin versus placebo. About Poster No. 1118 - Sub-population of Hispanic/Latino Adults with T2D: The findings from the first presentation were derived from six randomized, double-blind, placebo-controlled phase III studies of linagliptin 5 mg/d given as monotherapy or in addition to common glucose-lowering therapies.(1) Of the six studies included in the analysis, two were 18 weeks in duration and four were 24 weeks in duration. A total of 731 American Hispanic/Latino patients (467 who received linagliptin and 264 who received placebo) were included in the full analysis set (FAS), which was comprised of all randomized patients treated with at least one dose of the study drug, and who had their HbA(1c) measured at baseline and at least once during the treatment period. The primary efficacy endpoint was change in HbA(1c) from baseline to 18 or 24 weeks. Baseline HbA(1c) levels were 8.25% in the linagliptin group and 8.23% in the placebo group. Key findings of the retrospective analysis for the linagliptin treatment group included: 0.58% reduction in HbA1c compared to placebo after 24 weeks of treatment (95% confidence interval [CI]-0.74, -0.42; p<0.0001) and 14.6% reported drug-related AEs vs. 18.4% for placebo. About Poster No. 1119 - Sub-population of Adults with Long-standing T2D: For the second retrospective analysis, researchers pooled data from two phase III studies of 202 patients with a reported T2D duration of >=10 years, who received either linagliptin 5 mg/d (n=122) or placebo (n=80). The average exposure to both treatments was 169 days. A total of 192 patients (117 linagliptin and 75 placebo) were included in the FAS. The primary endpoint was change in HbA(1c) from baseline to 24 weeks. Baseline HbA(1c) levels were 8.07% in the linagliptin group and 8.45% in the placebo group.(2) Key findings of the retrospective analysis for the linagliptin treatment group included(2): 0.66% reduction in HbA1c compared to placebo after 24 weeks of treatment (CI: -0.95, -0.38; p<0.0001) and 21.3% reported treatment-related AEs vs. 16.3% in the placebo arm.